Arrowhead Pharmaceuticals vs Mirum Pharmaceuticals
ARWR and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and MIRM compare
Arrowhead Pharmaceuticals is the larger company, worth 1.5 times as much as Mirum Pharmaceuticals ($8.5B against $5.5B).
Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus 16.8% for Arrowhead Pharmaceuticals).
Arrowhead Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −47.8% compared with −139% at Mirum Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | MIRM |
|---|---|---|
| Size and price | ||
| Market cap | $8.5B | $5.5B |
| Share price | $59.90 | $85.00 |
| Change, 1 year | 48.7% | 20.6% |
| Change, 5 years | −25.8% | 424% |
| Beta (5Y) | 1.73 | 0.67 |
| Employees | 711 | 372 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.6× | 8.9× (better) |
| P/B | 18.2× | – |
| FCF yield | −0.89% (better) | −4.1% |
| Fair value | $32.22 | – |
| Margin of safety | −85.9% | – |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 44.0% (better) |
| Revenue growth, 5Y average | 56.6% | – |
| Profitability | ||
| Operating margin | −33.8% (better) | −135% |
| Net margin | −47.8% (better) | −139% |
| FCF margin | −11.2% (better) | −37.0% |
| Return on equity | −64.8% (better) | −703% |
| Financial health | ||
| Interest coverage | −2.4× (better) | −62.1× |
| Current ratio | 5.90 (better) | 2.86 |
| Altman Z-score | 2.56 (better) | −0.47 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 110% |
| Held by insiders | 4.0% | 9.2% |
| Insider net buying, 12 months | −$37.3M | −$33.2M (better) |
| Short interest, % of float | 7.9% | 11.8% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.